Medivation Inc.

Medivation Inc. announced that clinical results from its first pivotal trial of Dimebon showed that behavioral symptoms were stabilized in patients with mild-to-moderate Alzheimer's disease (AD) over a one-year period, resulting in decreased caregiver distress. Benefits of Dimebon were seen across most behavioral symptoms and were most prominent in the symptoms of depression, apathy, hallucinations, irritability and motor disturbance. The data presented at the AAGP conference included results of an analysis of the 12 subdomains of the Neuropsychiatric Inventory (NPI), a measure of the behavioral symptoms of AD. During the study, the NPI was assessed at the beginning of the study and at weeks 12, 26, 39 and 52. Results showed that Dimebon-treated patients were significantly improved on the NPI total score compared with placebo-treated patients after six months (p=0.01) and one year of treatment (p=0.04). Dimebon treatment resulted in improvement over placebo on 8 of the 12 individual NPI subdomains.